Abcellera Biologics Inc (ABCL) — Cash Flow Quality Index

Latest as of September 2022: -4.76x

Abcellera Biologics Inc (ABCL) has a Cash Flow Quality Index of -4.76x as of September 2022. Operating cash flow of $-126.79 Million is below net income of $26.62 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore Abcellera Biologics Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.

Cash Flow Quality Index

-4.76x
Operating CF / Net Income

Operating Cash Flow

$-126.79 Million
USD

Net Income

$26.62 Million
USD

Data as of

Sep 2022
Most recent filing

Abcellera Biologics Inc Cash Flow Quality Index (2018–2022)

Historical Cash Flow Quality Index for Abcellera Biologics Inc across 4 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Abcellera Biologics Inc (ABCL) tangible net worth to evaluate the tangible quality of the company's equity base.

Annual Cash Flow Quality Index for Abcellera Biologics Inc (2018–2022)

Year-by-year earnings quality comparison for Abcellera Biologics Inc. For live market cap and the full company financial profile, see Abcellera Biologics Inc market capitalisation.

Year Quality Index Operating CF (USD) Net Income YoY Change
2022 1.75x $277.36 Million $158.52 Million ▲ +9.8%
2021 1.59x $244.58 Million $153.46 Million ▲ +735.3%
2020 0.19x $22.69 Million $118.92 Million ▼ -98.3%
2018 11.54x $3.56 Million $309.00K
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.